A new medical commentary published in The Lancet examines proton therapy as a treatment option for oropharyngeal cancer, focusing on its potential to reduce treatment-related side effects. The commentary discusses how definitive chemoradiotherapy remains the standard treatment for locally advanced oropharyngeal squamous-cell carcinoma.
The medical field has already seen significant improvements in reducing treatment toxicity through the transition from 3D conformal radiotherapy to intensity-modulated radiotherapy (IMRT). This shift fundamentally transformed outcomes by reducing xerostomia and long-term swallowing dysfunction in head and neck cancer patients.